Biochemical and pharmacological activities of zetidoline (DL 308‐IT): a new antidopaminergic agent

D. Barone,N. Corsico,A. Diena,A. Restelli,A. Glasser,F. Rodenghi
DOI: https://doi.org/10.1111/j.2042-7158.1982.tb04205.x
1982-02-01
Abstract:Zetidoline (DL 308-IT, 1-(3-chlorophenyl)-3-[2-3,3dimethyl-l-azetidinyl)ethyl]imidazolidin-2-one HCI I) is a member of a novel group of dopamine antagonists (Fontanella et al 1981). pharmacologically active in animals (Diena & Allocca 1980) and man (Szabadi et a1 1980) in tests predictive of potential antipsychotic activity. We show that D L 308-IT differs fundamentally from some other neuroleptic drugs in lacking the ability to inhibit dopamineinduced stimulation of striatal adenylate cyclase. and in its weaker ability to displace [3H]spiroperidol from cerebral dopamine binding sites in vitro. Yet. in vivo. it displays the characteristic biochemical and pharmacological profile of a potent dopamine antagonist.
What problem does this paper attempt to address?